Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6month course of TNF inhibitors prospective intervention study and partial economic evaluation

Scandinavian Journal of Rheumatology

Volumn 38, Issue 4, 2009, Pages 246-250

  Hoving, J L ^a   Bartelds, G M ^b   Sluiter, J K ^a   Sadiraj, K ^a   Groot, I ^a   Lems, W F ^c   Dijkmans, B A C ^b,c   Wijbrandts, C A ^a   Tak, P P ^a   Nurmohamed, M T ^b   Voskuyl, A E ^c   Fringsdresen, M H W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WORK CAPACITY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERVENTION STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WORK;

EID: 70350651605     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740902748264     Document Type: Article

References (15)

1. Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö , Sweden. Scand J Rheumatol 2007;36:179-183
2. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006;35:415-425
3. Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: A pilot study of workplace challenges and successful adaptations. Arthritis Care Res 2000;13:89-99.
4. Katz PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995;8:272-278
5. Van Veldhoven MJPM, Meijman TF. [Questionnaire on psychosocial job demands and job stress], in Dutch. Amsterdam: NIA, 1994.
6. Balder B, Lindholm NB, Lowhagen O, Palmqvist M, Plaschke P, Tunsater A, et al. Predictors of self-assessed work ability among subjects with recent-onset asthma. Respir Med 1998;92:729-734
7. De Jong Z, Van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997;36:878-883
8. Beurskens AJ, BultmannU, Kant I,Vercoulen JH, Bleijenberg G, Swaen GM. Fatigue among working people: Validity of a questionnaire measure. Occup EnvironMed 2000;57:353-357
9. van Veldhoven VM, Broersen S. Measurement quality and validity of the 'need for recovery scale'. Occup Environ Med 2003;60(Suppl 1):i3-i9.
10. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health careprogrammes, 3rd edn. Oxford:OxfordUniversityPress, 2005.
11. Mushkin SJ. Health as an investment. J Polit Econ 1962;70:129-157
12. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005;3:CD005113.
13. Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006;55:287-293
14. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
15. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-722